Multiple Fractures in an Infant With Hepatoblastoma and Beckwith-Wiedemann Syndrome

Toni Eimicke1, Jonathan Swartz2

  • 1Pediatric Endocrinology, The Barbara Bush Children's Hospital at Maine Medical Center, Portland, ME 04102, USA.

JCEM Case Reports
|November 1, 2023
PubMed

Insights

Children with hepatoblastoma experience more fractures. A premature infant with Beckwith-Wiedemann syndrome and hepatoblastoma showed fracture healing after zoledronic acid (ZA) treatment, suggesting a potential therapeutic role.

Area of Science:

  • Pediatric Oncology
  • Pediatric Endocrinology
  • Pediatric Orthopedics

Background:

  • Hepatoblastoma in children is associated with an increased incidence of fractures.
  • Limited data exist on the specific causes and management of fractures in this population.

Observation:

  • A premature 4-month-old infant with Beckwith-Wiedemann syndrome and hepatoblastoma presented with multiple severe fractures.
  • While prematurity and metabolic bone disease were considered, they did not fully explain the fracture severity.

Findings:

  • The patient received chemotherapy and surgical resection for hepatoblastoma.
  • Following treatment with zoledronic acid (ZA), skeletal surveys showed fracture healing and no new fractures.
  • Long-term follow-up indicated continued absence of new fractures and appropriate motor development.

Implications:

  • This case highlights the potential for zoledronic acid (ZA) in managing pathological fractures in pediatric cancer patients.
  • Understanding compounded fracture risks (prematurity, chronic illness, hepatoblastoma) is crucial for prevention and treatment strategies.
  • Further research is needed to elucidate fracture pathophysiology and guide preventative measures in hepatoblastoma patients.